IN8BIO, INC. — Director's Dealing 2025

May 8, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: IN8BIO, INC. (INAB)
CIK: 0001740279
Period of Report: 2025-04-27

Reporting Person: Ho William Tai-Wei (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-04-27	Series B Warrants (right to buy)	$1.50	D	81967	Disposed	2028-12-13	Common Stock (81967)	Direct
2025-04-27	Series B Warrants (right to buy)	$0.45	A	81967	Acquired	2028-12-13	Common Stock (81967)	Direct
2025-05-01	Series A Warrants (right to buy)	$0.45	D	81967	Disposed	2025-10-04	Common Stock (81967)	Direct
2025-05-01	Pre-Funded Warrant (right to buy)	$0.0001	A	81967	Acquired		Common Stock (81967)	Direct

Footnotes

F1: The reported transaction involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on December 13, 2023 with an exercise price of $1.50 per share. The exercise price was reduced to $0.45 per share.

F2: Fully vested and exercisable.

F3: The reported securities are included within 81,967 units purchased by the Reporting Person on December 13, 2023 for $1.22 per Unit. Each Unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to
purchase 81,967 shares of common stock.

F4: Pursuant to an Exchange Letter Agreement, dated April 26, 2025 (the "Exchange Agreement"), by and between the Company and the Reporting Person, the Reporting Person surrendered to the Company for cancellation the Series A Warrants for a like number of Pre-Funded Warrants to purchase common stock, with a per share exercise price of $0.0001 per share.

F5: The reported securities are included within 81,967 units purchased by the Reporting Person on December 13, 2023 for $1.22 per unit. Each unit consists of one share of common stock, one Series A warrant and one Series B warrant, each warrant represents the right to purchase 81,967 shares of common stock.

F6: The Pre-Funded Warrants have no expiration date and are exercisable at any time after the date of issuance. The Pre-Funded Warrants are subject to certain exercise limitations.